Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.30 |
| ▸ | HTR2B | P41595 | 2/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13579265 | 0.95 | CNR2 (0.31) | — | |
| SCHEMBL13579261 | 0.94 | KDM1A (0.31) | — | |
| SCHEMBL7043278 | 0.90 | FPR2 (0.33) | FPR2HTR2CHTR2BHTR2A | |
| SCHEMBL13579264 | 0.90 | FPR2 (0.30) | FPR2 | |
| SCHEMBL13579274 | 0.89 | HTR2C (0.33) | HTR2CHTR2BHTR2A | |
| SCHEMBL13579259 | 0.88 | ALDH1A1 (0.32) | — | |
| SCHEMBL12759367 | 0.86 | GABRA1 (0.34) | GABRA1GABRB2 | |
| SCHEMBL12759954 | 0.85 | GABRA1 (0.33) | GABRA1GABRB2 | |
| SCHEMBL13579269 | 0.85 | SPHK1 (0.30) | — | |
| SCHEMBL13579262 | 0.83 | KDM1A (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372306-B2 | Liquid crystal compound having negative dielectric anisotropy, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2013-02-12 | — | — | US | disclosed |
| US-8372306-B2 | Liquid crystal compound having negative dielectric anisotropy, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2013-02-12 | — | — | US | disclosed |
| US-20090324854-A1 | LIQUID CRYSTAL COMPOUND HAVING NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090324854-A1 | LIQUID CRYSTAL COMPOUND HAVING NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324854-A1 | LIQUID CRYSTAL COMPOUND HAVING NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CTNND1, YWHAZ, OCIAD2 | GABRA1 3208/4885GABRB2 3377/4885FPR2 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.